DK2158901T3 - Alpha-aztreonamlysinat - Google Patents

Alpha-aztreonamlysinat Download PDF

Info

Publication number
DK2158901T3
DK2158901T3 DK09015300.8T DK09015300T DK2158901T3 DK 2158901 T3 DK2158901 T3 DK 2158901T3 DK 09015300 T DK09015300 T DK 09015300T DK 2158901 T3 DK2158901 T3 DK 2158901T3
Authority
DK
Denmark
Prior art keywords
aztreonam
lysinate
aztreonam lysinate
formulation
solution
Prior art date
Application number
DK09015300.8T
Other languages
English (en)
Inventor
Alan Bruce Montgomery
Frank-Christophe Lintz
Manfred Keller
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34083679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2158901(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/613,639 external-priority patent/US7214364B2/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK2158901T3 publication Critical patent/DK2158901T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (4)

1. Todelsrekonsti tutionssystem, hvor (a) den første del er en frysetørret doseringsform, der består af aztreonamlysinat fremstillet af a-aztreonam, og (b) den anden del, der er til stede som en bestanddel, er en fortynding, der er 0,1 til 0,9 N saltvandsopløsning.
2. Todelssystem ifølge krav 1 til anvendelse i en fremgangsmåde til behandling af en lungeinfektion forårsaget af gramnegative bakterier hos et menneske.
3. Todelssystem til anvendelse ifølge krav 2, hvor den gramnegative bakterie er Pseudomonas aeruginosa.
4. Todelssystem til anvendelse ifølge krav 2, hvor den gramnegative bakterie er Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans eller multilægemiddelresistent Pseudomonas aeruginosa.
DK09015300.8T 2003-07-03 2004-07-01 Alpha-aztreonamlysinat DK2158901T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/613,639 US7214364B2 (en) 2000-12-27 2003-07-03 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US10/882,985 US7138419B2 (en) 2000-12-27 2004-06-30 Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
EP04777564.8A EP1641436B2 (en) 2003-07-03 2004-07-01 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Publications (1)

Publication Number Publication Date
DK2158901T3 true DK2158901T3 (da) 2018-01-15

Family

ID=34083679

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09015300.8T DK2158901T3 (da) 2003-07-03 2004-07-01 Alpha-aztreonamlysinat
DK04777564.8T DK1641436T4 (da) 2003-07-03 2004-07-01 Inhalerbar aztreonamlysinatformulering til behandling af og forebyggelse mod bakterielle lungeinfektioner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04777564.8T DK1641436T4 (da) 2003-07-03 2004-07-01 Inhalerbar aztreonamlysinatformulering til behandling af og forebyggelse mod bakterielle lungeinfektioner

Country Status (14)

Country Link
US (1) US7138419B2 (da)
EP (3) EP2452672A3 (da)
JP (1) JP2007527398A (da)
BR (1) BRPI0411949A (da)
CA (1) CA2530774C (da)
CY (2) CY1114621T1 (da)
DK (2) DK2158901T3 (da)
ES (2) ES2428030T5 (da)
HK (1) HK1089359A1 (da)
HU (2) HUE035150T2 (da)
PL (2) PL2158901T3 (da)
PT (2) PT1641436E (da)
SI (2) SI1641436T2 (da)
WO (1) WO2005007132A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) † 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
CA2433280C (en) * 2000-12-27 2010-09-21 Salus Pharma, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
ES2351651B2 (es) * 2003-07-02 2011-09-28 Gilead Sciences Inc. Método para la determinación de impurezas en una sal de lisina de aztreonám amorfa.
WO2005005424A1 (en) * 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101951906A (zh) * 2007-10-01 2011-01-19 吉里德科学公司 用于治疗肺病中的健康相关生命质量缺陷的吸入式氨曲南赖氨酸
CN101912356B (zh) * 2010-08-02 2012-01-11 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
ES2956367T3 (es) * 2010-09-17 2023-12-20 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fago antibacteriano, péptidos de fago y sus métodos de uso
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2012212269B2 (en) * 2011-01-31 2016-05-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AU2014239959A1 (en) * 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
CN107805618B (zh) * 2017-12-03 2021-04-06 李峰 一种改造盐碱地耕种性的微生物菌剂及其制备方法
CN110857474B (zh) * 2018-08-24 2023-04-18 武汉远大弘元股份有限公司 L-半胱氨酸盐酸盐一水合物的处理方法
US20220142866A1 (en) * 2019-02-28 2022-05-12 Exorao Life Science S.R.L. Sterile aztreonam package

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US3984403A (en) † 1972-06-30 1976-10-05 Takeda Chemical Industries, Ltd. Arginine and lysine salts of acid cephalosporins
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4826973A (en) 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
DK0754050T3 (da) 1994-01-14 2002-10-21 Xoma Technology Ltd Anti-gram-positive bakterielle fremgangsmåder og materialer
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
ATE461692T1 (de) 1999-10-29 2010-04-15 Novartis Ag Trockenpulverzusammensetzungen mit verbesserter dispersität
CA2433280C (en) * 2000-12-27 2010-09-21 Salus Pharma, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) † 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
JP2005525375A (ja) 2002-03-05 2005-08-25 トランセイブ， インク． 生物活性物質をリポソーム又は脂質複合体内に封入する方法
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
WO2005005424A1 (en) * 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof

Also Published As

Publication number Publication date
EP2158901B1 (en) 2017-10-18
PT1641436E (pt) 2013-11-07
EP1641436A1 (en) 2006-04-05
SI1641436T1 (sl) 2013-12-31
SI2158901T1 (en) 2018-02-28
BRPI0411949A (pt) 2006-08-29
ES2428030T3 (es) 2013-11-05
WO2005007132A1 (en) 2005-01-27
DK1641436T3 (da) 2013-09-30
EP2452672A3 (en) 2013-11-06
PL1641436T3 (pl) 2014-02-28
US7138419B2 (en) 2006-11-21
EP1641436B2 (en) 2017-05-10
CY1114621T1 (el) 2016-10-05
PL1641436T5 (pl) 2017-10-31
HUE035150T2 (en) 2018-05-02
CY1119753T1 (el) 2018-06-27
SI1641436T2 (sl) 2017-08-31
DK1641436T4 (da) 2017-07-17
EP1641436B1 (en) 2013-09-04
PT2158901T (pt) 2018-01-15
EP2452672A2 (en) 2012-05-16
JP2007527398A (ja) 2007-09-27
PL2158901T3 (pl) 2018-05-30
HK1089359A1 (en) 2006-12-01
EP2158901A2 (en) 2010-03-03
ES2655036T3 (es) 2018-02-16
CA2530774A1 (en) 2005-01-27
EP2158901A3 (en) 2010-03-17
US20050063912A1 (en) 2005-03-24
HUS1800012I1 (hu) 2018-03-28
ES2428030T5 (es) 2017-07-25
CA2530774C (en) 2011-10-18

Similar Documents

Publication Publication Date Title
US9345663B2 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7208141B2 (en) Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections
AU2002231244A1 (en) Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
DK2158901T3 (da) Alpha-aztreonamlysinat
AU2014271333B2 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2009233632C1 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2012202089A1 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections